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Introduction
The protein tyrosine kinase Pyk2 (also designated RAFTK, 
CADTK, and CTK) and FAK are two members of a distinct 
family of nonreceptor tyrosine kinases. PYK2 and FAK share 
 45% amino acid sequence identity and a common domain 
structure: an N-terminal FERM domain followed by a protein 
tyrosine kinase (PTK) domain, three proline-rich regions, and 
a focal adhesion targeting (FAT) domain at the C terminus. 
Although FAK is expressed in most cells (Richardson and 
Parsons, 1996), Pyk2 exhibits a more restricted expression pat-
tern with strongest expression in the central nervous system and 
in hematopoietic cells (Lev et al., 1995). FAK is a major intra-
cellular signaling component of integrin-mediated cell adhesion 
(Schlaepfer et al., 1999) and plays a role in signaling pathways 
mediated by growth factor receptors. PYK2, on the other hand, 
is activated by a variety of extracellular cues including agonists 
of G protein–coupled receptors, intracellular Ca
+2 concentration, 
infl  ammatory cytokines, and stress signals, as well as integrin-
mediated cell adhesion (Lev et al., 1995; Schlaepfer et al., 1999).
Pyk2 is highly expressed in osteoclasts, where it is pri-
marily confi  ned to podosomes (Duong et al., 1998; Williams 
and Ridley, 2000; Pfaff and Jurdic, 2001). Podosomes are highly 
dynamic, actin-rich structures that mediate cell attachment and 
migration of highly motile cells such as macrophages and osteo-
clasts. They are composed of a central actin-bundle core sur-
rounded by integrins and integrin-associated adhesion molecules 
(Linder and Aepfelbacher, 2003). When plated on glass, mature 
osteoclasts organize their podosomes at the periphery of the cell 
in a large belt-like structure. The podosome belt is similar to the 
sealing zone, another podosome-containing structure that is 
formed in active bone-resorbing osteoclasts (Luxenburg et al., 
2007). Both structures share the same molecular components 
and are stabilized by microtubules (Destaing et al., 2003, 2005). 
Reduction of Pyk2 expression in osteoclasts by adenovirus con-
taining Pyk2 antisense RNA leads to impairment in integrin-
mediated cytoskeletal organization and bone resorption (Duong 
et al., 2001). In addition, macrophages from Pyk2
−/− mice failed 
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to become polarized and to migrate in response to chemokine 
stimulation in vitro and in vivo (Okigaki et al., 2003). It has 
been proposed that a ternary Pyk2-Src-Cbl complex induced by 
integrin engagement plays an important role in the control of 
osteoclast migration and bone resorption (Sanjay et al., 2001; 
Miyazaki et al., 2004). However, it is not clear how signaling 
via Pyk2 is linked to changes in the osteoclast cytoskeleton, and 
in particular to podosome assembly and organization, processes 
required for bone resorption.
Here, we report that Pyk2 defi  ciency in mice leads to an 
osteopetrotic phenotype. Osteoclasts from Pyk2
−/− mice are de-
fective in cell polarization, fail to form proper sealing zones, 
and ineffi  ciently resorb dentin in vitro. Furthermore, Pyk2-null 
osteoclasts fail to form a podosome belt that is typically seen at 
the periphery of wild-type osteoclasts. We also demonstrate that 
Rho activity is increased and the cellular distribution and stabil-
ity of microtubules are compromised in Pyk2-null osteoclasts. 
Ectopic expression of wild-type or Pyk2 mutants in Pyk2-null 
osteoclasts demonstrates that the FAT domain of Pyk2 plays a 
primary role in the control of podosome belt and sealing zone 
formation, as well as in bone resorption. These experiments show 
that Pyk2, by controlling Rho activity, regulates microtubule-
dependent podosome organization in osteoclasts and thereby 
bone resorption.
Results
Pyk2
−/− mice are osteopetrotic
We have previously described the generation of Pyk2
−/− mice 
and demonstrated that Pyk2 defi  ciency results in impairment in 
multiple macrophage functions (Okigaki et al., 2003). Because 
Pyk2 is abundantly expressed in osteoclasts, we have examined 
the possibility of whether defi  ciency in Pyk2 may result in bone 
abnormalities. Immunoblotting of osteoclast lysates with anti-
Pyk2 antibodies revealed the presence of both the ubiquitous 
(110 kD) and hematopoietic (106 kD) Pyk2 isoforms, which 
have been shown to be generated by alternative RNA splicing 
(Dikic et al., 1998) (Fig. 1 A). Histological and histomorpho-
metric comparison showed that the size and shape of bones 
from Pyk2
−/− mice are normal. The length and width of the 
  femur at the metaphyseal mid-point of either 2- or 10-wk-old 
mice were similar, and no changes were detected in the prolifer-
ative or hypertrophic zones of growth plates (unpublished data). 
However, the density of bones of either 2- or 10-wk-old Pyk2
−/− 
mice was substantially elevated throughout the skeleton as shown 
by X-ray analysis and by histology (Fig. 1, B and C). Histomor-
phometric analysis demonstrated higher trabecular bone volume 
in Pyk2
−/− mice (Fig. 1 D). The increase in trabecular bone volume 
is largely due to increased trabecular number (Fig. 1 E) and to a 
Figure 1.  Pyk2
−/− mice are osteopetrotic. (A) Immunoblotting of protein 
lysates from wild-type and Pyk2-null osteoclasts using anti-Pyk2 antibodies. 
Top band is the ubiquitous isform of Pyk2 and the bottom band is the Pyk2 
isoform expressed in hematopoietic cells. (B) Longitudinal section of repre-
sentative tibiae from 10-wk-old wild-type and Pyk2
−/− mice, stained ac-
cording to the method of Von Kossa. The color of mineralized matrix is 
black. White square shows the metaphyseal region used for histomor-
phometry. (C) X-ray analysis of tibiae and femora from 10-wk-old wild-type 
and Pyk2
−/− mice. Notice increased bone density in the femoral metaphy-
sis of Pyk2
−/− mice, compared with wild-type (arrowhead). (D–J) Quantita-
tive histomorphometry of proximal tibiae from 2- and 10-wk-old wild-type 
(black) and Pyk2
−/− (white) mice. BV/TV, trabecular bone volume (% bone 
volume) (d); TbN, trabecular number (e); TbTh, trabecular thickness (f); 
TbSp, trabecular spacing (g); OcS/BS, osteoclast surface (% of bone sur-
face) (h); ObS/BS, osteoblast surface (% of bone surface) (i); BFR/BS, 
bone formation rate (j). Bars show means ± SEM. n = 8–10 for each 
group, *, P < 0.05; **, P < 0.01; ***, P < 0.001, as determined by 
two-way ANOVA. (K) Alcian blue staining of proximal tibial growth plates 
from 10-wk-old wild-type and pyk2
−/− mice. Note the un-remodeled carti-
lage in the trabecular bone of Pyk2
−/− mice (blue). Bar, 20 μm.DEFECTIVE OSTEOCLAST FUNCTION IN PYK2
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lesser extent to increased trabecular thickness, more evident in 
10-wk-old Pyk2
−/− mice (Fig. 1 F), whereas trabecular spac-
ing was reduced at both time points (Fig. 1 G).
Although trabecular bone volume was high, the percent-
age of trabecular bone surface covered by osteoclasts (osteo-
clast surface) was substantially elevated in Pyk2
−/− mice, by 
60% in 2-wk-old mice, and by nearly 300% in 10-wk-old mice 
(Fig. 1 H). Elevated osteoclast surface in the presence of high 
trabecular bone volume suggests a defect in osteoclast function, 
as shown in several osteopetrotic mutants (Soriano et al., 1991; 
McHugh et al., 2000; Hollberg et al., 2002). Gain of trabecular 
bone volume may also result from high bone formation caused 
by changes in osteoblast differentiation or function. A mildly 
elevated osteoblast surface (percentage of trabecular bone cov-
ered by osteoblasts) was detected in 2-wk-old Pyk2
−/− mice, but 
both osteoblast surface and bone formation rates (determined 
by measuring incorporation of calcium-binding fl  uorochromes) 
were normal in 10-wk-old mice (Fig. 1, I and J, respectively), while 
their trabecular bone volume continued to increase. Although 
at this time we cannot completely rule out a minor effect of 
Pyk2 defi  ciency on osteoblast function, our results strongly 
support the notion that impairment in osteoclast function is the 
primary cause of the bone phenotype of Pyk2
−/− mice. Indeed, and 
strongly supporting this conclusion, abundant cartilage remnants 
were detected in the trabeculae of 10-wk-old Pyk2
−/− mice 
(Fig. 1 K). This may result from defective resorption of the 
growth plate cartilage, and is an important hallmark of osteo-
petrosis (Walker, 1975; Helfrich et al., 1991).
Pyk2-null osteoclasts exhibit a cell-
autonomous defect in bone resorption
To examine whether the osteopetrosis of Pyk2
−/− mice is indeed 
caused by defective osteoclast function, osteoclasts isolated 
from wild-type or Pyk2
−/− mice were plated on dentin, and their 
ability to form pits was compared. After 48 h, the area, depth, 
and volume of the pits were compared using three-dimensional 
scanning confocal microscopy. The volume of dentin excavated 
by Pyk2-null osteoclasts was signifi  cantly reduced (Fig. 2 A). 
The decrease in pit volume resulted from a decrease in both area 
and depth; the pits formed by Pyk2-null osteoclasts were more 
shallow (Fig. 2, A and B). Thus, in the absence of Pyk2, osteoclasts 
show a cell-autonomous decrease in bone-resorbing activity.
To gain further insight into the mechanism underlying 
the reduced resorption by Pyk2-null osteoclasts, we compared 
the distribution and status of cytoskeletal proteins in osteo-
clasts from wild-type or Pyk2
−/− mice. Immunofl  uorescence 
microscopy of osteoclasts plated on dentin and stained with 
fl  uorescently labeled phalloidin demonstrated that Pyk2-null 
Figure 2.  Defective bone resorption and altered cytoskeletal 
organization in Pyk2-null osteoclasts. (A) Osteoclasts isolated 
from wild-type and Pyk2-null mice were plated on dentin slices 
and allowed to excavate pits. Average area, depth, and vol-
ume of pits resorbed by wild-type and Pyk2-null osteoclasts 
were measured and analyzed using a violet laser color 3D 
proﬁ  le confocal microscope. Data are presented as means ± 
SD; n =6 from two individual experiments, ***, P < 0.001 
as determined by t test. (B) Views of resorption pits from ran-
domly chosen sites in dentin slices resorbed by wild-type or 
Pyk2-null osteoclasts, as viewed by color laser 3D proﬁ  le con-
focal microscope. Blue color represents deeper resorbed area, 
red represents a more shallow region. (C) Disrupted polariza-
tion of Pyk2-null osteoclasts on bone. Authentic osteoclasts 
were isolated from wild-type and Pyk2-null newborn mice, 
plated on dentin slices, and allowed to resorb. Cells on slices 
were ﬁ  xed and labeled for F-actin (shown in red). Bar, 10 μm. 
(D) Pyk2-null osteoclasts show podosome clusters and rings but 
almost no belts. Wild-type and Pyk2-null spleen-derived osteo-
clasts were differentiated on coverslips for 8 d, ﬁ  xed, and la-
beled for F-actin (left) and Pyk2 (right). Note clusters and small 
rings in Pyk2-null osteoclasts (bottom left), as opposed to pe-
ripheral podosome belt in wild-type cells, in which Pyk2 is 
localized (two top panels). Bar, 20 μm. (E) Quantiﬁ  cation of 
percentage of cells with podosome clusters/rings (white) and 
belts (black) in wild-type and Pyk2-null osteoclasts from two in-
dividual experiments performed as above. A total of 1,500 
osteoclasts were counted. Results are presented as means ± 
SD, ***, P < 0.001 as determined by t test. (f) Co-localization 
of cortactin or vinculin with actin in podosome clusters from 
wild-type and Pyk2-null osteoclasts (left panels) and XZ series 
(longitudinal view) of individual podosomes (right panels). Bar, 
15 μm in left panel and 1 μm in XZ panel. JCB • VOLUME 178 • NUMBER 6 • 2007  1056
osteoclasts formed an abnormal, thinner and smaller sealing 
zone (Fig. 2 C). Furthermore, immunofl  uorescent labeling of 
osteoclasts plated on glass demonstrated that in wild-type os-
teoclasts, F-actin was primarily localized in a podosome belt at 
the periphery of the cells, whereas in osteoclasts from Pyk2
−/− 
mice, actin was organized in podosome clusters and multiple 
small rings throughout the cell (Fig. 2, D and E). Cellular local-
ization of actin, cortactin, vinculin, and paxillin in podosomes 
using fl  uorescence microscopy have demonstrated that their dis-
tribution is similar in wild-type and Pyk2-null podosomes (Fig. 
2 F and Fig. S1, available at http://www.jcb.org/cgi/  content/full/
jcb.200701148/DC1). These experiments show that in absence 
of Pyk2, podosomes fail to organize in a belt-like structure at the 
periphery of the cell. The defect in organization of podosomes 
also correlates with the presence of abnormal sealing zones in 
Pyk2-null osteoclasts, which may explain the shallower resorp-
tion cavities formed by Pyk2-null osteoclasts in vitro.
The defect of Pyk2-null osteoclasts 
is not osteoblast dependent
To further determine whether the defect in Pyk2-null osteoclasts 
is cell autonomous, we co-cultured different combinations of 
wild-type or Pyk2-null bone marrow cells and calvarial osteo-
blasts, allowing marrow-derived osteoclast precursor cells to 
differentiate into osteoclasts (Takahashi et al., 1988). As shown 
in Fig. 3, absence of podosome belt, revealed by both F-actin 
and vinculin staining, was detected in osteoclasts derived from 
Pyk2
−/− marrow whether in the presence of wild-type or Pyk2-
null osteoblasts (Fig. 3 A). The number of osteoclasts generated 
from Pyk2
−/− bone marrow was not signifi  cantly different from 
wild-type, regardless of the origin of the supporting osteoblasts 
(Fig. 3 B). Collectively, these results demonstrate that osteoclast 
differentiation is unaffected by the absence of Pyk2, and that the 
functional defect in Pyk2-null osteoclasts is cell autonomous.
Actin and podosome dynamics are altered 
in Pyk2-null osteoclasts
The dynamic nature of GFP-labeled actin that was expressed in 
osteoclasts from wild-type or Pyk2
−/− mice was compared by 
fl  uorescence recovery after photobleaching (FRAP) measure-
ments (Axelrod et al., 1976). Characteristic photobleaching re-
covery time of GFP-actin in wild-type osteoclasts was  30 s, as 
described previously (Destaing et al., 2003). In contrast, the 
photobleaching recovery time of GFP-actin in Pyk2-null osteo-
clasts was doubled (Fig. 4 A), indicating that the rate of actin 
fl  ux in podosomes is reduced in the absence of Pyk2. The mo-
lecular mechanisms underlying the observed differences in 
FRAP measurements is currently unknown. Notwithstanding 
the decreased rate of actin fl  ux in individual podosomes, the total 
podosome life-span (namely, the average time from the fi  rst 
 appearance of a new podosome to its dissociation) in osteoclasts 
expressing GFP-actin was not signifi  cantly different (Fig. 4 B). 
Overall, these results suggest that in osteoclasts, Pyk2 contrib-
utes to the dynamic exchange of actin in podosomes, but not to 
podosome life span. The podosome organization defects in 
Pyk2-null osteoclasts, which prevent podosome belt formation, 
are unlikely to be caused by a change in podosome life span in 
these cells.
Microtubule stability and acetylation are 
altered in osteoclasts from Pyk2
−/− mice
Previous analyses have shown that the process of podosome 
patterning is controlled by the microtubule network in osteo-
clasts (Destaing et al., 2003). During podosome differentiation, 
podosomes initially organize into clusters that evolve into unstable 
small podosome rings by a mechanism of self-organization. 
Subsequently, the small rings fuse and expand by an oriented 
treadmilling process toward the periphery of the cell to form 
belts. Thus, the pattern of podosomes in Pyk2-null osteoclasts 
Figure 3.  Pyk2-null osteoclasts are inherently defective. Osteoblasts from wild-type or Pyk2
−/− mice were co-cultured with bone marrow cells of either 
  genotype, and allowed to differentiate in culture. (A) Fluorescence micrographs of the cells showing multiple nuclei of differentiated osteoclasts (blue), F-actin 
(red), and vinculin (green). Bar, 20 μm. (B) Parallel cocultures were stained for TRAP, and TRAP-positive cells containing three or more nuclei were counted. 
Experiment was preformed in triplicate and repeated twice with similar results. (C) Pyk2 expression in cells. Osteoblasts were separated from osteoclasts 
by gentle pipetting and lysates from the osteoblasts and osteoclasts were subjected to immunoblotting with anti-Pyk2 antibodies. DEFECTIVE OSTEOCLAST FUNCTION IN PYK2
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resembles earlier stages of osteoclast differentiation, when podo-
somes are organized in clusters and small, dynamic podosome 
rings. It was demonstrated that the transition of clusters/rings to 
peripheral podosome belt requires an intact microtubule net-
work (Destaing et al., 2003). We therefore analyzed microtubule 
distribution and found that Pyk2-null osteoclasts lacked the 
characteristic circular microtubule network that is concentrated 
around the podosome belt in normal cells (Turksen et al., 1988; 
Destaing et al., 2003), while maintaining the radial network of 
microtubules (Fig. 5 A).
Cellular microtubules are composed of two distinct pools 
with regard to their stability: a short-lived pool with a half-life 
of  5–10 min and a more stable pool that may last for as long as 
several hours. The stable microtubule pool is resistant to treat-
ment with the microtubule-depolymerizing agent nocodazole 
and contributes to podosome belt stabilization in osteoclasts 
(Westermann and Weber, 2003; Destaing et al., 2005). As expected, 
wild-type osteoclasts contained a nocodazole-resistant pool of 
stable microtubules. In contrast, very few nocodazole-resistant 
microtubules were seen in Pyk2-null osteoclasts, demonstrating 
that the short-lived, rather than the stable pool, is the predom-
inant form of microtubules in cells lacking Pyk2 (Fig. 5 B). 
Figure 4.  Actin and podosome dynamics in wild-type and Pyk2-null osteo-
clasts. (A) FRAP analysis of podosomes of wild-type or Pyk2-null osteo-
clasts. Mature osteoclasts were microinjected with expression vector for 
GFP-actin, after which GFP-actin in podosome clusters was photobleached 
in deﬁ  ned regions (a rectangle of 5 × 2.5 μm) and allowed to recover. 
The time of recovery of ﬂ  uorescence in single podosomes that existed during 
the whole recovery time was measured, and the average characteristic 
time of recovery was calculated for podosomes in wild-type and Pyk2-null 
cells. (characteristic time of recovery refers to the inverse of the constant k2 
(1/ k2 in the equation I(t) = I(0) + k1e
-k
2
t, used to ﬁ  t the curve of ﬂ  uorescence 
recovery). 45 measurements per condition in 13 cells each were analyzed, 
in two independent experiments. Results are presented as means ± SD. 
***, P < 0.01 as determined by t test. (B) Differentiated wild-type and 
Pyk2-null osteoclasts were microinjected with expression vector for GFP-actin 
and observed by time-lapse microscopy. Individual podosomes in clusters 
were followed, and their life span (the overall time in which a ﬂ  uorescently 
labeled podosome exists), was calculated and plotted. 150 measurements 
of each wild-type and Pyk2-null osteoclasts were performed, from a total of 
6–7 cells each, in two independent experiments. Results are presented as 
means ± SD.
Figure 5.  Microtubule stability and acetylation are altered in Pyk2-null 
osteoclasts. (A) Wild-type or Pyk2-null osteoclasts were ﬁ  xed, permeabilized, 
and labeled with rhodamine-phalloidin (red) or anti-tubulin antibodies 
(green). Bar, 15 μm. (B) Differentiated wild-type and Pyk2-null osteoclasts 
were treated for 45 min in 2 μM nocodazole, ﬁ  xed, and labeled with 
rhodamine-phalloidin (left panels) or anti-tubulin antibodies (center panels). 
Bar, 15 μm. (C) Mature wild-type and Pyk2-null osteoclasts were ﬁ  xed, permea-
bilized, and labeled with rhodamine-phalloidin (red) or with anti-acetylated 
tubulin antibodies (green). Bar, 15 μm. (D) Cell lysates from wild-type or 
Pyk2-null osteoclasts were immunoblotted with anti-acetylated tubulin anti-
bodies (top). The blot was stripped and re-probed with anti-tubulin (middle) 
and anti-actin (bottom) antibodies, for loading controls.JCB • VOLUME 178 • NUMBER 6 • 2007  1058
Because the stable pool of microtubules that   accumulates during 
osteoclastogenesis is highly acetylated (Destaing et al., 2005), we 
next analyzed microtubule acetylation by immunofl  uorescence 
microscopy of permeabilized cells labeled with antibodies 
specifi  c for the acetylated form of tubulin. This experiment 
showed that microtubule acetylation is reduced in Pyk2-null 
osteoclasts (Fig. 5 C). A similar conclusion was drawn by 
immunoblotting experiments demonstrating that acetylation 
of microtubules is, indeed, compromised in Pyk2
−/− osteo-
clasts (Fig. 5 D). The reduced acetylation of microtubules in 
Pyk2-null osteoclasts is consistent with their reduced stabil-
ity, as revealed by nocodazole treatment. It was shown that 
microtubule acetylation is regulated by the mDia2-HDAC6 com-
plex in osteoclasts (Destaing et al., 2005). However, analyses 
of mDia2 localization in wild-type and Pyk2-null osteoclasts 
using fl  uorescence microscopy revealed similar cellular distri-
bution (Fig. S4, available at http://www.jcb.org/cgi/content/full/
jcb.200701148/DC1).
Enhanced Rho activity in Pyk2-null 
osteoclasts
The small GTPase Rho has been implicated in the stabilization 
and post-translational modifi  cation of microtubules (Palazzo 
et al., 2004). In addition, Rho inhibition leads to enhancement 
in the acetylation and stabilization of the microtubule network 
in osteoclasts (Destaing et al., 2005). To examine the possibility 
of whether the reduced stability and acetylation of microtubules 
in Pyk2-null osteoclasts are caused by increased Rho activation, 
Rho activity was determined by using a GST fusion protein 
containing the Rho binding domain of Rhotekin (RBD) to pull 
down the active, GTP-bound form of Rho (Ren et al., 1999). 
The results showed increased Rho activity in Pyk2-null cells 
(Fig. 6 A). The potential role of Rho activation was further 
tested by examining the effect of the Rho inhibitor C3-toxin on 
the stability of microtubules, and on podosome belt formation. 
The experiment presented in Fig. 6 B shows that C3-toxin treat-
ment increased the stable pool of microtubules and induced the 
formation of a belt-like structure at the cell periphery of Pyk2-
null osteoclasts. The stable pool of microtubules observed in 
Pyk2-null osteoclasts after treatment with C3 was also highly 
acetylated (Fig. 6 C). These results further indicate that enhanced 
Rho activity in Pyk2-null osteoclasts is responsible for the decrease 
in microtubule stability and acetylation, and   impairment of podo-
some belt formation.
Lack of podosome belt in Pyk2-null 
osteoclasts cannot be rescued 
by activated Src
It was previously proposed that recruitment of Src by Pyk2 
plays an important role in podosome belt formation and bone 
resorption in osteoclasts (Lakkakorpi et al., 2003; Miyazaki 
et al., 2004). Examination of the expression and activity of Src in 
wild-type and Pyk2-null osteoclasts revealed that, although the 
expression of Src was not altered in the absence of Pyk2 (Fig. 
7 A), Src activity was reduced in both unstimulated and integrin-
stimulated Pyk2-null osteoclasts (Fig. 7 B). However, podo-
some belt formation was not rescued in Pyk2-null osteoclasts 
that were microinjected with expression vector for activated Src 
(Src-Y527F) (Fig. 7 C), suggesting that the Pyk2-dependent 
pathway leading to microtubule-dependent podosome belt and 
sealing zone formation in osteoclasts is, by and large, a Src-
independent process.
Figure 6.  Enhanced Rho activity and reduced 
microtubule acetylation in Pyk2-null osteoclasts. 
(A) Lysates from wild-type or Pyk2-null osteoclasts 
were subjected to a pull-down assay using GST-
RBD. The amount of RBD-bound Rho and total Rho 
in cell lysates was determined by immunoblotting 
with anti-Rho antibodies. The ratio of GTP-bound 
Rho to total Rho was determined by densitometry. 
Shown is a representative of three individual ex-
periments. (B) Rho inhibition by C3 toxin promotes 
podosome belt formation and microtubules stabili-
zation in Pyk2-null osteoclasts. Pyk2-null osteoclasts 
were left untreated, or treated with 5 μg/ml C3 
for 5.5 h with or without 2 μM nocodazole for 
the last 35 min. Cells were ﬁ  xed and labeled with 
rhodamine-phalloidin (top) or anti-tubulin antibodies 
(bottom). Wild-type cells were treated with C3 and 
nocodazole, as control (left). Note the appearance 
of podosomes in a belt-like structure in Pyk2-null 
osteoclasts after C3 treatment (arrows, middle panel, 
top) and appearance of nocodazole-resistant micro-
tubules in Pyk2-null osteoclasts treated with C3 
plus nocodazole (compare two bottom panels in 
bottom right). Bar, 15 μm. (C) Wild-type and Pyk2-
null osteoclasts were treated with C3 as described 
above, ﬁ   xed, permeabilized, and labeled with 
anti-acetylated tubulin antibodies. Bar, 15 μm.DEFECTIVE OSTEOCLAST FUNCTION IN PYK2
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The Pyk2-𝖫FAT mutant does not rescue 
podosome belt formation and 
bone resorption
To determine which Pyk2 domain(s) regulate podosome belt 
formation, we tested the ability of several Pyk2 mutants to res-
cue podosome belt formation in Pyk2-null osteoclasts. We tested 
Pyk2-Y402F, an autophosphorylation site mutant that does not 
bind Src; Pyk2-K457A, a kinase-negative mutant; Pyk2-∆FAT 
(aa 1–868), a deletion mutant devoid of the FAT domain; Pyk2-
∆FERM (aa 381–1009), a deletion mutant that lacks the FERM 
domain; and, as a control, Pyk2-WT (Fig. 8 A). The differ-
ent mutants were transiently expressed in HEK293 cells and 
their tyrosine kinase activity was analyzed by immunoblotting 
with antibodies specifi  c for phosphorylated Tyr402 of Pyk2. 
All   mutants except Pyk2-Y402F and Pyk2-K457A showed similar 
levels of autophosphorylation (Fig. S2 a, available at http://www
.jcb.org/cgi/content/full/jcb.200701148/DC1). As expected, 
Pyk2-WT, Pyk2-∆FAT, and Pyk2-∆FERM formed a complex 
with Src, whereas the Pyk2-Y402F and Pyk2-K457A mutants 
failed to bind Src to a substantial degree (Fig. S2, b and c).
Figure 7.  Lack of podosome belt in Pyk2-null osteoclasts cannot be rescued 
by activated Src. (A) Immunoblotting of lysates from wild-type or Pyk2-null 
osteoclasts with anti-FAK or anti-Src antibodies. (B) Left panels: Src was 
  immunoprecipitated with anti-Src antibodies from lysates of wild-type or Pyk2-
null osteoclasts followed by immunoblotting with either anti-pY418 anti-
bodies directed against Src autophosphorylation site (top) or with anti-Src 
antibodies for detection of the total amount immunoprecipitated Src (bottom). 
Right: wild-type or Pyk2-null osteoclasts were suspended by EDTA treatment. 
After 30 min the suspended cells were attached to serum-coated plates for 1 h. 
Cell lysates were subjected to immunoprecipitation with anti-Src antibodies 
followed by immunoblotting with either anti-pY418 or anti-Src antibodies. 
The ratio between activated Src to total Src was determined by densitometry. 
(C) Wild-type and Pyk2-null osteoclasts were microinjected with expression 
vectors for Src-Y527F and GFP-paxillin as expression control. Cells were 
ﬁ  xed, permeabilized, and labeled with anti-Src antibodies or with rhodamine-
phalloidin. More than 75% of the cells expressing Y527F-Src and GFP-paxillin 
did not show any podosome belt or rings. The remaining cells showed small 
rings, but no belt was seen in any of the cells. Bar, 15 μm. 
Figure 8.  The Pyk2-𝖫FAT mutant does not rescue podosome belt formation. 
(A) Schematic representation of Pyk2 mutants used in this study. Pyk2-
WT, wild-type; Pyk2-∆FAT, deletion mutant lacking the FAT domain (aa 
869–1009); Pyk2-∆FERM, deletion mutant lacking the FERM domain of 
(aa 1–380); Pyk2-Y402F, point mutation in Src SH2 domain binding site; 
Pyk2-K457A, a kinase negative mutant. (B–F) Pyk2-null osteoclasts were 
microinjected with expression vectors for wild-type (b) or different Pyk2 
mutants (C–F). Cells were ﬁ  xed, permeabilized, and labeled with anti-Pyk2 
antibodies or rhodamine-phalloidin. Right panels show merged images 
(Pyk2 in green, F-actin in red). Bar, 15 μm. (G) Pyk2-null osteoclasts were 
infected with adenovirus carrying wild-type or Pyk2 mutants. Cells were 
lysed and the expression of Pyk2 proteins was revealed by immunoblotting 
with anti-Pyk2 antibodies and compared with the expression level of 
  endogenous Pyk2 in wild-type osteoclasts. (H) Pyk2-null osteoclasts were 
infected with adenovirus carrying wild-type or Pyk2 mutants, and the num-
ber of cells bearing podosome belts at the cell periphery was counted. 
Results are presented as a percentage of control (WT-Pyk2). 800 cells were 
counted for each group.JCB • VOLUME 178 • NUMBER 6 • 2007  1060
We next examined the ability of the different mutants to 
rescue podosome belt formation in Pyk2-null osteoclasts. Expres-
sion vectors for the different mutants were microinjected into 
osteoclasts from Pyk2
−/− mice, and the cells were stained with 
fl  uorescently labeled phalloidin and anti-Pyk2 antibodies. Micro-
injection of Pyk2-WT cDNA completely rescued podosome belt 
formation in Pyk2-null osteoclasts (Fig. 8 B), providing further 
evidence that Pyk2 is required for the formation of the peripheral 
podosome belt in osteoclasts. Similar results were observed when 
Pyk2-null osteoclasts were microinjected with Pyk2-∆FERM, 
Pyk2-Y402F, or Pyk2-K457A cDNAs (Fig. 8, D–F). In contrast, 
podosome belt formation was not observed in Pyk2-null osteo-
clasts that were microinjected with Pyk2-∆FAT. Instead, podosome 
clusters and small rings were seen throughout the microinjected 
osteoclasts (Fig. 8 C). Examination of the cellular distribution of 
ectopically expressed Pyk2 molecules showed, however, that both 
wild-type and all mutant Pyk2 were confi  ned to actin-containing 
podosomes, including the Pyk2-∆FAT mutant (Fig. S3, available 
at http://www.jcb.org/cgi/content/full/jcb.200701148/DC1).
Similar results were obtained when Pyk2-null osteoclasts 
were infected with adenovirus containing wild-type Pyk2 or the 
different Pyk2 mutants, and matched for expression levels of 
endogenous Pyk2 (Fig. 8 G). Comparison of the infected cells 
demonstrated that only Pyk2-∆FAT failed to induce belt forma-
tion in comparison to belt formation induced by wild-type Pyk2 
(Fig. 8 H). In agreement with that, expression of Pyk2-∆FAT 
was not able to either restore Rho activation or stabilization of 
microtubules, as demonstrated by a nocodazole-resistance as-
say (Fig. 9, A and B, respectively). The lack of a podosome belt 
in Pyk2-null osteoclasts infected with the Pyk2-∆FAT virus cor-
related with the absence of sealing zone in these cells after 
replating on dentin, as shown in Fig. 10 A.
The effect of Pyk2 mutants on osteoclast function was 
then examined in a resorption assay. Expression of Pyk2-
∆FERM in Pyk2-null osteoclasts completely rescued their 
bone-resorbing activity. On the other hand, the bone-resorbing 
activity was only partially restored by the Pyk2-Y402F and 
Pyk2-K457A mutants, notwithstanding the complete restora-
tion of podosome belt formation by these mutants (Fig. 10). The 
area, depth, and volume of pits formed by Pyk2-null osteoclasts 
that were infected with Pyk2-∆FAT virus were signifi  cantly re-
duced (Fig. 10, B–D), further confi  rming the importance of the 
FAT domain in promoting osteoclast function. These results 
suggest that although Src recruitment and Pyk2 kinase activity 
contribute to bone resorption, the FAT domain of Pyk2 plays a 
major role in podosome organization and bone resorption.
Discussion
We have previously reported that Pyk2 defi  ciency results in 
impairment of macrophage function (Okigaki et al., 2003). Here, 
we report that Pyk2 defi  ciency also leads to osteopetrotic pheno-
type by impairment in the bone-resorbing activity of osteo-
clasts. In addition, experiments are presented demonstrating 
that Rho activity, microtubule stabilization and podosome orga-
nization are altered in Pyk2-null osteoclasts. Although we can-
not exclude the contribution of osteoblasts to the increased bone 
mass, the accumulation of cartilage remnants despite elevated 
osteoclast numbers confi  rm in vivo an impairment in osteoclast 
function. Furthermore, the in vitro experiments establish the 
fact that Pyk2-null osteoclasts are defi  cient in cytoskeletal orga-
nization and bone resorption, in a cell-autonomous manner. 
Thus, Pyk2 plays a critical role in podosome organization and 
osteoclast function.
Analysis of the cellular distribution of Pyk2 by immuno-
fl  uorescence microscopy showed that Pyk2 is preferentially 
localized in the periphery of osteoclasts in a region that overlaps 
with the podosome belt, when the cells are plated on glass, or 
the similar sealing zone, when plated on mineralized bone. 
Comparison of the cellular distribution of actin revealed that 
Pyk2 defi  ciency results in impairment in the formation of podo-
some belt and sealing zone in osteoclasts. Instead, Pyk2-null 
osteoclasts contain multiple podosome clusters and small podo-
some rings throughout the cell.
Given that a link has been established between micro-
tubules and actin organization (Waterman-Storer and Salmon, 
1999), we have explored the possibility of whether microtubule 
distribution and/or dynamics were altered in osteoclasts defi  cient 
in Pyk2. Immunofl  uorescence studies showed that the cellular 
distribution of microtubules is signifi  cantly altered in Pyk2-null 
osteoclasts; while Pyk2-null osteoclasts retained the radial net-
work, they lost their circular microtubule network that is usually 
Figure 9.  Expression of Pyk2-𝖫FAT mutant does not rescue Rho activation 
and microtubule acetylation in Pyk2-null osteoclasts. (A) HEK293 cells 
were transfected with expression vectors for WT-Pyk2 together with myc-
tagged Rho or with expression vectors for ∆FAT-Pyk2 together with myc-
tagged Rho. Analysis of Rho activity was performed as described in Fig. 6. 
Shown is a representative of two experiments. (B) Pyk2-null osteoclasts in-
fected with adenovirus carrying either wild-type or the ∆FAT-Pyk2 mutant 
were treated with 2 μM nocodazole for 45 min, after which the cells were 
ﬁ  xed, permeabilized, and labeled with anti-tubulin, rhodamine-phalloidin 
(red), or anti-Pyk2 antibodies (green).DEFECTIVE OSTEOCLAST FUNCTION IN PYK2
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seen at the periphery of osteoclasts. The stable, nocodazole-
resistant pool of microtubules that has previously been impli-
cated in mediating the transition from podosome clusters and 
rings into the peripheral podosome belt (Destaing et al., 2003), 
was nearly eliminated in Pyk2-null osteoclasts. Consistent with 
this fi  nding, the acetylation of microtubules, which correlates 
with microtubule stabilization, was also markedly reduced in 
Pyk2-null osteoclasts. Microtubule acetylation is controlled in 
Figure 10.  Reduced bone resorption in Pyk2-null osteoclasts expressing a Pyk2-𝖫FAT mutant. (A) Pyk2-null osteoclasts were infected with adenovirus 
carrying either wild-type or Pyk2 mutants. The infected cells were detached and replated on dentin for 36 h, ﬁ  xed, permeabilized, and labeled with rhoda-
mine-phalloidin (red) or with anti-Pyk2 antibodies (blue). Noninfected wild-type and Pyk2-null osteoclasts are shown in the top two panels as control. 
(B) Infected Pyk2-null osteoclasts were detached and replated on dentin for 48 h and allowed to excavate pits. Pit volume was measured and analyzed using violet 
laser color 3D proﬁ  le confocal microscope. Results were normalized to the number of TRAP-positive cells in each sample, and are represented as means ± SD, rel-
ative to cells infected with Pyk2-WT adenovirus. n = 6 from two independent experiments. *, P < 0.05; **, P < 0.01, ***, P < 0.001, as determined by t test.JCB • VOLUME 178 • NUMBER 6 • 2007  1062
part by the activity of histone and microtubule deacetylase 
HDAC6, which in turn is regulated by the small GTPase Rho 
(Destaing et al., 2005). We found that Pyk2 defi  ciency results in 
increased Rho activity, and established that this leads to reduced 
microtubule acetylation and reduced microtubule stability. 
We propose that Pyk2 may function as an upstream inhibitor of 
this signaling pathway in osteoclasts, which ultimately allows 
the transition of podosomes from the center of the cells, where 
they form clusters and small internal podosome rings, to the 
periphery, where they form a podosome belt and sealing zone, a 
structure necessary for effi  cient bone resorption.
During directional migration of fi  broblasts, the stable pool 
of microtubules becomes oriented toward the leading edge of 
the cell (Gundersen and Bulinski, 1988). Moreover, the micro-
tubules of fi  broblasts are post-translationally modifi  ed, and as 
in osteoclasts, the modifi  cations are associated with enhanced 
  microtubule stability (Westermann and Weber, 2003). In addi-
tion, FAK activation in the leading edge of fi  broblasts leads to 
enhanced Rho activity and microtubule stability (Palazzo et al., 
2004). In osteoclasts, on the other hand, enhanced stimulation of 
microtubule stability and podosome organization are controlled 
by Pyk2-mediated reduced Rho activation. Although the reason 
for this difference is unknown, this could be explained by differ-
ent effects of Pyk2 and FAK on Rho activation, or, as suggested 
before (Destaing et al., 2005), could be due to cell type–specifi  c 
effects of Rho inhibition on microtubule stability.
Ectopic expression of wild-type Pyk2 in Pyk2-null osteo-
clasts, at levels comparable to endogenous expression of the 
protein in wild-type cells, rescued the formation of a podosome 
belt and sealing zone as well as bone resorption. The cellular 
responses were also rescued by expression of a deletion mutant of 
Pyk2 lacking the FERM domain. Podosome belt formation was 
rescued by expression of a kinase-negative Pyk2 mutant (K457A) 
and by a point mutant in a tyrosine phosphorylation site (Y402F) 
that is responsible for mediating complex formation with Src. 
In contrast, a deletion mutant devoid of the FAT domain was not 
able to rescue normal responses in Pyk2-null osteoclasts, empha-
sizing the importance of this domain in the regulation of micro-
tubule stability and podosome organization in these cells.
It was previously shown that the FAT domain is responsi-
ble for Pyk2 localization in focal contacts of fi  broblasts and 
HeLa cells (Schaller and Sasaki, 1997; Xiong et al., 1998; Litvak 
et al., 2000). However, a deletion mutant of Pyk2 devoid of the 
FAT domain remains localized around the actin-rich podosome 
core in Pyk2-null osteoclasts, suggesting that the inability of 
mutant protein to rescue podosome belt or sealing zone forma-
tion and bone resorption are not caused by a defect in cellular 
distribution. The FAT domain of Pyk2 may participate in podo-
some belt formation by regulating the activities of guanine 
  nucleotide exchange factors or GTPase-activating proteins (GAPs) 
that regulate Rho activity, resulting in the control of acetylation 
and stabilization of microtubules in the pathways mentioned 
earlier in the Discussion, thereby regulating osteoclast cytoskeletal 
organization and bone resorption.
The rescue of Pyk2-dependent podosome belt formation 
in Pyk2-null osteoclasts by the kinase-negative Pyk2 mutant 
suggests that Pyk2 may function as a platform for recruitment 
and assembly of signaling proteins in addition to its function as 
tyrosine kinase. Accordingly, other tyrosine kinases may com-
pensate for the loss of intrinsic tyrosine kinase activity of Pyk2 
by trans-phosphorylation of key tyrosine residues that function 
as docking sites for signaling proteins. Pyk2 may also recruit 
signaling proteins in a phosphorylation-independent manner 
through interactions mediated by its proline-rich region with 
SH3 domain–containing signaling proteins.
The effect of overexpression of Pyk2-Y402F in wild-type 
osteoclasts was previously described (Lakkakorpi et al., 2003; 
Miyazaki et al., 2004), demonstrating that osteoclasts that over-
express this mutant fail to form podosome belt and show re-
duced bone resorption in vitro. Consistently, as demonstrated in 
our paper, in the absence of endogenous Pyk2, Pyk2-Y402F can 
partially restore bone resorption, but completely restores the 
formation of a peripheral podosome belt. This, together with the 
fi  nding that microinjection of Src-Y527F into Pyk2-null osteo-
clasts cannot rescue podosome belt formation, suggests that 
Pyk2 may mediate two separate pathways: a Rho-dependent 
pathway that regulates microtubule-dependent podosome orga-
nization, and a Src-dependent pathway that may be involved in 
other functions related to bone resorption, such as actin dynamics, 
cell attachment, or ruffl  ed border formation.
We also show that actin dynamics are altered in the absence 
of Pyk2; the rate of incorporation of GFP-actin into podosomes 
in photobleached areas is slowed down by an approximately 
twofold in the absence of Pyk2. Previous reports have inter-
preted slower actin fl  uxes as an indication of reduced actin poly-
merization (Destaing et al., 2003), which could result from the 
inhibition of actin polymerizing proteins or from enhanced actin 
severing along the fi  laments. The role of actin polymerization 
in podosome formation and function is still poorly understood, 
but it has been suggested that polymerization induces a force 
that pushes the cell membrane toward the substrate (Prass et al., 
2006; Footer et al., 2007), a process that may also be essential 
for attachment of osteoclasts to their substrate and therefore to 
bone resorption.
Finally, the ruffl  ed border is a membrane-rich organelle 
that is surrounded by the sealing zone, and through which pro-
tons and proteolytic enzymes are secreted to resorb the bone 
matrix. We have observed in Pyk2-null osteoclasts a shorter and 
irregular ruffl  ed border structure and defective translocation of 
the proton pump to this region in Pyk2-null osteoclasts (unpub-
lished data). This may explain the shallow pits formed by Pyk2-
null osteoclasts, and may suggest additional, yet unknown roles 
of Pyk2 in osteoclast function and bone resorption.
In conclusion, this study demonstrates that Pyk2 is required 
for normal organization of the cytoskeleton in osteoclasts, and 
bone resorption. In the absence of Pyk2, Rho activity is increased, 
microtubule acetylation and stabilization are decreased, and tran-
sition of podosomes to the periphery of the cell is prevented.
Materials and methods
Generation of knockout mice
Generation of Pyk2
−/− mice was described previously (Okigaki et al., 
2003). Animals were handled in accordance with the guidelines of Yale 
University Institutional Animal Care and Use Committee.DEFECTIVE OSTEOCLAST FUNCTION IN PYK2
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Histomorphometry
Bone samples were collected for histomorphometric analysis at 2 and 10 wk 
of age. Double-ﬂ  uorochrome labeling was performed in 10-wk-old mice 
as described previously (Sims et al., 2000); animals were injected with 
calcein (20 mg/kg body weight) followed by the same dose of demeclocy-
cline at 10 and 3 d before tissue collection, respectively. Tibiae and femora 
were collected, ﬁ   xed in 3.7% formaldehyde in PBS, and embedded in 
methylmethacrylate as described previously (Sims et al., 2000). 5-μm sec-
tions were stained with Toluidine blue or Alcian blue or by the Von Kossa 
method, or analyzed unstained for ﬂ  uorochrome labels. Histomorphometric 
analysis was performed according to standard procedures using the Os-
teomeasure system (OsteoMetrics, Inc.) in the proximal tibiae. Tibial corti-
cal thickness and periosteal mineral appositional rates were measured as 
described previously (Sims et al., 2000). Femoral length and width were 
determined from contact X-rays that were scanned and measured using 
NIH Image 2.0.
Reagents
Mouse MCSF and RANKL were obtained from R&D systems. Nocodazole 
was obtained from Sigma-Aldrich. Cell-permeable C3 was obtained from 
Cytoskeleton, Inc. Monoclonal anti-Pyk2 and anti-FAK antibodies were pur-
chased from Transduction Laboratories. Anti-pY402 Pyk2 and anti-pY418 
Src antibodies were from Biosource International. Anti-v-Src monoclonal 
antibody was from Calbiochem. Monoclonal anti-RhoA antibody (26C4) 
was purchased from Santa Cruz Biotechnology, Inc. Anti–α-tubulin was 
from Abcam. Anti-acetylated tubulin was from Sigma-Aldrich. Anti-actin 
antibody was from Chemicon. Texas red– and rhodamine-conjugated phal-
loidin and secondary antibodies for immunoﬂ  uorescence were purchased 
from Invitrogen.
Plasmids and recombinant adenovirus
pEGFP-actin was obtained from CLONTECH Laboratories, Inc. pShuttle 
plasmids containing Pyk2-WT (wild-type Pyk2), Pyk2-Y402F (mutation in 
Src SH2-domain binding site), Pyk2-K457A (a kinase-negative mutant), 
Pyk2-∆FAT (deletion mutant devoid of the FAT domain), and Pyk2-∆FERM 
(deletion mutant devoid of the FERM domain) were used for transfection 
and microinjection experiments. Recombinant adenoviruses expressing the 
above mutants were prepared by recombination of the above plasmids us-
ing the Adenovator Vector System (Qbiogene) according to the manufac-
turer’s instructions.
Preparation of osteoclast cultures
Authentic osteoclasts from 2–4-d-old neonatal mice and co-culture osteo-
clasts from 6–8-wk-old mice were prepared as described previously (Sanjay 
et al., 2001). Spleen leukocyte cells were prepared and differentiated in 
culture using MCSF and RANK ligand as described previously (Destaing 
et al., 2003).
Microinjection
Mouse spleen cell–derived osteoclasts were transferred to observation me-
dium (a-MEM without bicarbonate containing 10% fetal calf serum, 20 mM 
Hepes, 20 ng/ml M-CSF, and 20 ng/ml of soluble recombinant RANK-L). 
Intranuclear microinjection of cDNAs (0.2 mg/ml in water) was performed 
at room temperature on an inverted microscope (model IX 71; Olympus) 
using an InjectMan NI2 micromanipulator and a FemtoJet Microinjector 
(Eppendorf). After microinjection, cells were maintained at 37°C and 5% CO2 
for at least 6 h in differentiation medium before imaging.
Time-lapse microscopy
Osteoclasts were differentiated in 35-mm glass-bottom Petri dishes, then 
transferred to observation medium. After microinjection of DNA coding for 
GFP-tagged actin, the dishes were placed on a 37°C heated stage (Carl 
Zeiss MicroImaging, Inc.) and cells were imaged with a microscope (Axiovert 
200M; Carl Zeiss MicroImaging, Inc.) containing a 40× (NA 1.0) Plan-
Apochromat objective, a 63× (NA 1.4) Plan NeoFluor objective, and 
equipped with a MicroMax 5-MHz camera (Princeton Instruments, Inc.). 
Meta Imaging Series 7.0 (Universal Imaging Corp.) was used to mount AVI 
movies from image stacks. Extracted images from stacks were processed 
(brightness/contrast adjustment) with Adobe Photoshop 6.0 and ImageJ.
Confocal microscopy and FRAP measurements
For immunoﬂ  uorescence, cells were ﬁ  xed with 4% paraformaldehyde diluted 
into PBS, pH 7.4, processed as described previously (Ory et al., 2000), and 
imaged with a microscope (LSM Meta; Carl Zeiss MicroImaging, Inc.) using 
a 63× (NA 1.4) Plan NeoFluor objective. To prevent cross-contamination 
between ﬂ  uorochromes, each channel was imaged sequentially using 
the multi-track recording module before merging.
FRAP experiments were performed on osteoclasts prepared as for 
regular videomicroscopy experiments using the same confocal setup de-
scribed previously. Bleaching time (3.2 s), acquisition rate (1 image every 
547 ms), and bleaching area were the same for all experiments. Image 
  extraction was performed with Meta Imaging Series (Universal Imaging 
Corp.). The ﬂ  uorescence recovery was measured only within podosome 
cores that existed during the whole recovery time. Fluorescence intensity at 
each time point was normalized to the starting ﬂ  uorescence intensity (pre-
bleach). To analyze recovery kinetics, FRAP measurements were ﬁ  tted to a 
single exponential curve (performed with Igor Pro 4.0; WaveMetrics) as 
described in Meyvis et al. (1999).
Immunoprecipitation and immunoblotting experiments
HEK293 cells were transfected using Lipofectamine (Invitrogen) according 
to the manufacturer’s instructions. Immunoprecipitation and immunoblotting 
were preformed as described previously (Okigaki et al., 2003).
GTP-Rho pull-down assay
GST fusion protein containing the Rho binding domain of rhotekin (RBD) 
was produced and used for pull-down experiments with osteoclast lysates 
as described previously (Ren et al., 1999).
Pit formation assay
Pit resorption assay was preformed as described previously (Miyazaki et al., 
2004). Three-dimensional proﬁ  les of resorbed pits were characterized by 
using a reﬂ   ective confocal laser scanning microscope (RCLSM) (model 
VK8510; Keyence) under the 50× objective lens (NA 0.8) interfaced via 
a CCD camera to “Virtual view 3D (version 2.5)” for making the three-
  dimensional reconstruction image proﬁ  le. The images were displayed at a 
resolution of 1024 × 768 pixels. Quantitative analysis of resorbed pit number, 
area, and volume were performed using Win ROOF image-analyzing 
software (version 5.5; Mitani Corp.) (Aoki et al., 2006).
Online supplemental material
Fig. S1 shows the distribution of paxillin in wild-type and Pyk2-null osteo-
clasts. Fig. S2 shows expression of the different mutants of Pyk2, their auto-
phosphorylation status, and their binding to Src. Fig. S3 shows the cellular 
distribution of actin and Pyk2 in osteoclasts microinjected with the different 
Pyk2 mutants. Fig. S4 shows localization of microinjected mDia2-GFP in wild-
type and Pyk2-null osteoclasts. Online supplemental material is available 
at http://www.jcb.org/cgi/content/full/jcb.200701148/DC1.
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